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A B S T R A C T
Background: Little is known about the functional mechanisms through which genetic loci associated with sub-
stance use traits ascertain their effect. This study aims to identify and functionally annotate loci associated with
substance use traits based on their role in genetic regulation of gene expression.
Methods: We evaluated expression Quantitative Trait Loci (eQTLs) from 13 brain regions and whole blood of the
Genotype-Tissue Expression (GTEx) database, and from whole blood of the Depression Genes and Networks
(DGN) database. The role of single eQTLs was examined for six substance use traits: alcohol consumption
(N=537,349), cigarettes per day (CPD; N=263,954), former vs. current smoker (N=312,821), age of
smoking initiation (N=262,990), ever smoker (N=632,802), and cocaine dependence (N=4,769).
Subsequently, we conducted a gene level analysis of gene expression on these substance use traits using S-
PrediXcan.
Results: Using an FDR-adjusted p-value<0.05 we found 2,976 novel candidate genetic loci for substance use
traits, and identified genes and tissues through which these loci potentially exert their effects. Using S-PrediXcan,
we identified significantly associated genes for all substance traits.
Discussion: Annotating genes based on transcriptomic regulation improves the identification and functional
characterization of candidate loci and genes for substance use traits.
1. Introduction
In recent years, large-scale genome-wide association studies
(GWAS) of substance use traits (i.e., substance use disorders and
quantitative measures of substance use) have been conducted
(Gelernter et al., 2014; Liu et al., 2019). These GWAS revealed multiple
genome-wide significant loci (p < 5.0 ⋅10−8). However, the GWAS
approach faces two major challenges. First, the effects of individual
single nucleotide polymorphisms (SNPs) are generally small, and a ty-
pical GWAS in which single-variant tests of association are performed is
generally underpowered to detect trait-associated SNPs with small ef-
fect sizes. One possible solution to this problem is to increase sample
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sizes by combining samples in GWAS meta-analyses (Evangelou and
Ioannidis, 2013), but even in these studies, the identified loci explain a
modest proportion of the trait variance in substance use traits (Liu
et al., 2019; Pasman et al., 2018). A second limitation of the GWAS
approach is that the functional relevance of identified SNPs remains
unclear. The majority (∼93 %) of trait-associated SNPs are located in
non-coding regions of the genome (Maurano et al., 2012) suggesting
that these SNPs act through the regulation of gene expression rather
than by altering the protein product. Furthermore, due to extensive
linkage disequilibrium (LD) in the genome, GWAS alone are unable to
distinguish causal variants from correlated non-functional variants
within an LD block. Constrained by these challenges, GWAS alone have
been largely unsuccessful in elucidating the biological mechanisms in-
volved in most substance use traits.
To facilitate the identification of biological mechanisms underlying
substance use traits, it is essential to study the genetic regulation of
gene expression in relevant tissues, i.e., human brain tissue from spe-
cific brain regions. The relevance of the brain for understanding the
etiology of substance use (and disorders) is supported by numerous
gene expression studies, which aimed to explore the role of epigenetic
regulation and the transcriptional machinery in the addicted brain. In
their review of these studies, Zhou et al. (Zhou et al., 2014) summarized
the findings of post-mortem human studies, including those that report
differences in gene expression in various brain regions between cases
with substance use disorder vs. non-addicted controls. Overall, the re-
viewed studies suggest a prominent role for mechanisms involved in
transcriptomic regulation (Albertson et al., 2004, 2006; Celentano
et al., 2009; Zhou et al., 2011).
However, in general differential expression analysis between cases
and controls does not reveal the direction of causality, i.e., it does not
answer the question whether altered gene expression in a brain region
represents susceptibility to substance dependence or whether excessive
substance use is responsible for the altered gene expression. Because a
large proportion of disease-associated variants exert their effects by
regulating gene expression (Maurano et al., 2012), we applied an in-
tegrative approach that combines transcriptome data with summary
statistics from recent GWAS to explore the role of regulatory genetic
variants in substance use traits. Genetic variants that are associated
with messenger RNA (mRNA) expression levels of one or more genes, in
one or more tissues, are known as “expression quantitative trait loci”
(eQTLs). The genes that are under the influence of at least one eQTL, in
one or more tissues are called eGenes. Two types of eQTLs have been
identified: cis-eQTLs, influencing expression levels of genes on the same
locus (located at± 1MB from the gene), and trans-eQTLs that have
their effect on genes at a different locus (e.g., those on a different
chromosome). Because the statistical power to detect trans-eQTLs is low
at current sample sizes, we focused only on cis-eQTLs. We determined
the eQTL status of 13 human brain tissues and whole blood using the
Genotype-Tissue Expression (GTEx) project, the most comprehensive
eQTL database available to date, in terms of the diversity of tissues
included (Consortium, 2018). GTEx (V7) provides samples from 53
different tissues, including 13 from the brain, obtained from post-
mortem adult subjects. In addition, we performed the same procedure
for whole blood eQTLs from the Depression Genes and Networks (DGN)
database (Battle et al., 2014).
In the current study, we investigated associations between cis-eQTLs
and substance use traits, by filtering GWAS variants on eQTL status for
specific brain regions and whole blood. This approach has several
benefits. First, it reduces the multiple-testing burden by focusing spe-
cifically on variants that are involved in genetic regulation, thereby
facilitating the identification of novel candidate variants which might
be especially beneficial for relatively small GWAS studies. Second,
functional interpretation of eQTLs is relatively straightforward because
an eQTL variant tags a causal regulatory variant of an eGene. Therefore,
the eGene targeted by the eQTL is a sensible target for future follow-up
studies. Third, by investigating whether eQTLs in particular tissues
(e.g., the brain or specific regions within the brain) are significant, we
obtain information on which (brain) tissues are involved in substance
use traits at a genetic level. Fourth, this method provides causal asso-
ciations between gene-expression and substance use, because eQTL-
gene expression associations have been evaluated in healthy in-
dividuals, and are thus not influenced by substance abuse. In addition
to this single variant approach, we conducted an integrative analysis to
investigate expression on a gene level using S-Predixcan (Barbeira et al.,
2018), which can provide further mechanistic insights into the sub-
stance use traits under investigation.
We analyzed eQTLs in 13 brain regions (i.e., amygdala, anterior
cingulate cortex, caudate, cerebellar hemisphere, cerebellum, cortex,
frontal cortex, hippocampus, hypothalamus, putamen, nucleus ac-
cumbens, substantia nigra, and cervical spine) and in whole blood as a
comparison tissue. The role of eQTLs was examined for six substance
use traits. We used summary statistics of the discovery samples ob-
tained from major GWAS for these traits (Gelernter et al., 2014; Liu
et al., 2019). The substance use traits examined in the current study
were included if sufficiently large GWAS (i.e.,> 4,000 subjects) are
available. The aims of this study were: i) to identify novel genetic loci
associated with these substance use traits; ii) to improve the functional
characterization of novel and known genetic loci; and iii) to obtain
information about the mediating effects of gene expression levels on
substance use traits by using a gene-level association approach.
2. Materials and methods
2.1. GWAS summary statistics
We obtained summary statistics from previously conducted GWAS
meta-analyses, all of which were based on large samples; alcohol con-
sumption (N=537,349), CPD (N=263,954), former vs. current
smoker (N=312,821), age of smoking initiation (N=262,990), ever
smoker (N=632,802), and cocaine dependence (N=4,769).
Information on subjects, sample preparation, and analytic methods can
be found in the original articles of the corresponding GWAS (Gelernter
et al., 2014; Liu et al., 2019). For some samples, genome-wide data was
only provided for the discovery samples, explaining the difference in
the number of subjects between the current study and the samples
described in the original papers. Detailed information about the sam-
ples is provided in Supplementary Table 1.
2.2. eQTL data
Details concerning the GTEx data used for this study are described
elsewhere (Aguet et al., 2016; Ardlie et al., 2015). To filter and anno-
tate SNPs of the GWAS summary statistics with eQTL information, we
downloaded significant SNP-gene associations (FDR-adjusted p-
value< 0.05; i.e., eQTL-eGene associations) for 13 brain tissues:
amygdala, anterior cingulate cortex, caudate, cerebellar hemisphere,
cerebellum, cortex, frontal cortex, hippocampus, hypothalamus, nu-
cleus accumbens, putamen, spine (cervical), substantia nigra, and
whole blood from the GTEx Portal V7 (http://www.gtexportal.org/
home/GTEx_Analysis_v7_eQTL.tar). The sample sizes varied across the
13 brain tissues (N ranges from 80 to 154); for whole blood the SNP-
gene associations were obtained from 369 individuals (Aguet et al.,
2016). Detailed information about the GTEx sample size per tissue and
the number of significant eQTLs and eGenes per tissue can be found in
Supplementary Table 2. DGN (N=922)(Battle et al., 2014) data con-
sists of a single tissue: whole blood. This data was used as an in-
dependent sample to conduct additional eQTL informed analyses. For
the DGN database we used the same method as for GTEx database de-
scribed above.
A.T. Marees, et al. Drug and Alcohol Dependence 206 (2020) 107703
2
2.3. Statistical analyses
For the single variant analyses we extracted those SNPs that are
eQTLs from the summary statistics of all GWAS. This extraction was
performed for each tissue. We applied the Benjamini-Hochberg False
Discovery Rate (FDR) approach (Benjamini and Hochberg, 1995),
which controls the expected proportion of false positives among all
signals with a FDR value below a fixed threshold, to determine sig-
nificance. Using the GTEx database, we applied FDR on all 14 tissues
combined for each of the six substance use traits, which provided us
with six sets of eQTLs with an FDR value. The single tissue DGN data set
was analysed separately, also using FDR. Subsequently, we determined
significant trait associations within those eQTL-sets using a FDR
threshold of q=0.05.
Significant eGenes were identified by applying the FDR 0.05
threshold on the eQTLs, and linking the eQTLs with significant trait
associations to the targeted eGenes. Since a single genetic locus can
include multiple eQTLs that are in high LD, we clumped eQTLs with
significant trait associations per tissue using PLINK2 (Chang et al.,
2015). As clumping cut-offs, we used an R2 of> 0.1 and a physical
distance of 1000 kb, which generated a list of “index” eQTLs (i.e., in-
dependent eQTLs), which we considered as distinct loci. Due to the
limited power all identified index eQTL, eGenes, and tissues should be
considered as candidate findings. Statistical analyses for the single
variants were performed using the open-source programming language
R (https://www.r-project.org/). For visualization, we used the R-library
“ggplot2″. To generate a heatmap, a matrix was generated based on the
R squared of the number of index eQTLs that met the trait-association
threshold of an FDR-adjusted p-value< 0.05. To investigate gene ex-
pression levels we used S-PrediXcan (Barbeira et al., 2018), which in-
tegrated eQTL information from summary statistics of the substance use
GWAS in an aggregated manner. S-PrediXcan estimates gene expression
weights by training a linear prediction model in samples with both gene
expression and SNP genotype data. Subsequently these weights are used
to predict gene expression from GWAS summary statistics, while in-
corporating the variance and co-variance of SNPs from an LD reference
panel. The current study used expression weights for the 14 tissues
central in this study from the GTEx Project (V7) and whole blood from
the DGN cohort (Battle et al., 2014; Gamazon et al., 2018), and LD
information from the 1000 Genome Project Phase 3 (Delaneau et al.,
2014). These data were processed with beta values and standard errors
from substance use summary statistics to estimate the expression-GWAS
association statistic. A Bonferroni correction was used to determine the
transcriptome-wide significant threshold (adjusting for all tissues and
genes per trait).
3. Results
The GWAS data sets of the six substance use traits used in this study
showed different levels of genetic signal when plotting all SNPs
(Supplementary Fig. 1). Alcohol consumption, CPD, ever smoker, age of
smoking initiation, and former vs. current smoker showed significant
trait associations (FDR-adjusted p-value<0.05). In contrast, cocaine
dependence did not reveal any trait associated SNPs in the full GWAS.
These results are largely in line with the original GWAS reports, and
serve to compare the full (i.e., ‘uninformed’) GWAS against the eQTL
informed GWAS analyses central in the current study.
After extracting GTEx eQTLs from the full GWAS summary statistics,
which reduced the multiple testing burden and focused on SNPs with
strong prior functional support, significant trait associations (FDR-ad-
justed p-value<0.05) were observed. Specifically, this was observed in
all tissues, for the following substance use traits: alcohol consumption,
CPD, ever smoker, age of smoking initiation, and former vs. current
smoker (Fig. 1, Table 1, and Supplementary Table 3), but no significant
trait associations were found for any tissue for cocaine dependence.
Using this methodology, we identified 2,976 (GTEx) and 811 (DGN)
novel loci (i.e., loci not identified in the uninformed GWAS of the six
substance use traits; FDR-adjusted p-value<0.05; Table 2). Moreover,
these eQTLs show evidence of exerting their effects in the various tis-
sues through numerous eGenes (Table 1, Supplementary Tables 3 and
4). Consistent over all substance use traits, we observed that eGenes
targeted by index eQTLs were generally different from the nearest gene
(Table 1 and Supplementary Table 3). In fact, in 66.3 % of the cases the
nearest gene was not the eGene in the GTEx informed analyses (i.e.,
analyses of GWAS summary statistics focusing only on GTEx eQTLs).
This suggests that proximity is a limited measure in determining the
functional relevance of a gene.
For alcohol consumption, we found eQTLs with significant trait
associations in all 14 GTEx tissues (Fig. 1), and identified considerably
more significant eGenes than for the other substance use traits (Sup-
plementary Table 5). In total, we identified 949 novel index eQTLs for
alcohol consumption, i.e. these SNPs were not significant in the unin-
formed GWAS.
For CPD, we found significant trait associations in all 14 GTEx tis-
sues. We identified 509 index eQTLs which were not identified in the
uninformed GWAS for CPD (Table 2). Many of the strongest associa-
tions were found in brain, and were located within the gene cluster:
IREB2-CHRNA3-CHRNA5-CHRNB4-HYKK-PSMA4 (Table 1, Supple-
mentary Table 3). For the other smoking traits (i.e., former vs. current
smoker, age of smoking initiation, ever vs. never smoker) we identified
117, 66, and 1,335 novel loci, respectively (Table 2). For these traits the
IREB2-CHRNA3-CHRNA5-CHRNB4-HYKK-PSMA4gene cluster showed
considerably weaker associations (Table 1, Supplementary Table 3).
Furthermore, the GTEx eQTL informed GWAS for cocaine dependence
did not reveal any significant trait associations, similar to the unin-
formed GWAS.
The single variant eQTL analyses informed by the DGN data,
showed 224 significant index eQTLs for alcohol consumption, 136 for
CPD, 401 for ever smoker, 25 for age of smoking initiation, and 35 for
former vs. current smoker, which were not found by the uninformed
GWAS (Table 2 and Supplementary Table 5). While the genes most
proximal to significant index eQTL based on DGN were occasionally
similar as found in the GTEx analyses, they often targeted different
Fig. 1. Heatmap of number of GTEx (sqrt transformed) index eQTLs with sig-
nificant trait association (FDR-adjusted p < 0.05) per tissue and per trait.
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eGenes. Comparing DGN to GTEx whole blood, different eGenes were
targeted by the same eQTL in 65.6 % of the cases.
The S-PrediXcan analyses, informed by the GTEx eQTLs, revealed
large numbers of significantly associated genes (corrected for the
number of genes and tissues) for alcohol consumption, CPD, age of
smoking initiation, ever smoker, and former vs. current smoker (Tables
3, 4 and Supplementary Table 6). For alcohol consumption, CPD, and
ever smoker, we found differentially expressed genes in all tissues
under investigation (Table 3). The identified genes of the S-PrediXcan
analyses showed evidence of tissue specificity, as many of our findings
were either unique to brain or to whole blood (Table 4). Moreover,
comparing the S-PrediXcan results informed by GTEx and DGN, we
observed many findings to be unique to a specific reference panel
(Supplementary Table 7).
4. Discussion
The overarching aim of this study was to explore whether func-
tionally annotating SNPs using information on their role in the reg-
ulation of gene expression facilitates the identification and functional
interpretation of candidate loci involved in substance use traits.
Furthermore, we aimed to identify genes with differentially genetically
regulated levels of gene expression associated with substance use traits.
Using the GTEx database we explored the role of regulatory genetic
variants in 14 different tissues and tested association with six substance
use traits. In addition, we conducted independent eQTL analyses using
the DGN database.
We identified index eQTLs with significant trait associations (FDR-
adjusted p-value<0.05) for five of the six traits examined: alcohol
consumption, CPD ever smoker, age of onset of smoking, former vs.
current smoker. For cocaine dependence, no GTEx eQTLs with sig-
nificant trait associations were found. Compared to the full (i.e., eQTL-
uninformed) GWAS results, functional annotation of eQTLs improved
the power to detect significant trait associations. Overall, informed by
GTEx, this method allowed us to identify 2,976 novel index eQTLs, we
interpret these index eQTLs as candidate loci for substance use traits.
These candidate loci were not previously detected by the uninformed
GWAS of the six substance use traits.
We will discuss a few highlights of our findings. For alcohol
Table 1
Overview of the five strongest eQTL-eGene relations per substance use trait, identified by the current study.
Alcohol consumption
Tissue Index eQTL PVALUE FDR GWAS effect GTEx slope Proximal gene eGene Distance to TSS (kb)*
Cerebellar Hemisphere rs28712821 1.10E-46 3.59E-40 −2.84E-02 −3.58E-01 ENSG00000134962 ENSG00000035928 46
Whole Blood rs35538052 3.23E-44 1.42E-38 2.80E-02 1.75E-01 ENSG00000134962 ENSG00000109814 −111
Cerebellum rs1260326 3.33E-33 4.18E-28 −2.33E-02 5.54E-01 ENSG00000084734 ENSG00000234072 152
Cerebellar Hemisphere rs1260326 3.33E-33 4.18E-28 −2.33E-02 5.00E-01 ENSG00000084734 ENSG00000234072 152
Whole blood rs1260326 3.33E-33 4.18E-28 −2.33E-02 −1.39E-01 ENSG00000084734 ENSG00000115216 80
CPD
Caudate rs8034191 4.80E-211 1.95E-205 −9.06E-02 −5.68E-01 ENSG00000188266 ENSG00000261762 −78
Caudate rs8034191 4.80E-211 1.95E-205 −9.06E-02 −5.90E-01 ENSG00000188266 ENSG00000169684 −52
Cortex rs8034191 4.80E-211 1.95E-205 −9.06E-02 −6.68E-01 ENSG00000188266 ENSG00000169684 −52
Frontal Cortex rs8034191 4.80E-211 1.95E-205 −9.06E-02 −6.44E-01 ENSG00000188266 ENSG00000169684 −52
Nucleus accumbens rs8034191 4.80E-211 1.95E-205 −9.06E-02 −6.11E-01 ENSG00000188266 ENSG00000169684 −52
Ever smoker
Brain Cerebellum rs1565735 3.42E-17 5.01E-12 1.76E-02 6.80E-01 ENSG00000234770 ENSG00000120903 89
Caudate rs1004787 5.27E-17 5.01E-12 −1.24E-02 −4.16E-01 ENSG00000259439 ENSG00000236502 −10
Anterior Cingulate Cortex rs240957 5.36E-17 5.01E-12 1.75E-02 −5.60E-01 ENSG00000271789 ENSG00000255389 −303
Cerebellum rs240957 5.36E-17 5.01E-12 1.75E-02 −4.12E-01 ENSG00000271789 ENSG00000009413 −187
Cortex rs6937734 5.56E-17 5.01E-12 1.59E-02 −4.35E-01 ENSG00000009413 ENSG00000009413 −68
Age of initiation
Whole Blood rs62177761 1.85E-10 4.55E-06 −1.91E-02 1.84E-01 ENSG00000143951 ENSG00000143951 −629
Nucleus accumbens rs1607204 2.02E-10 4.55E-06 1.89E-02 −3.15E-01 ENSG00000143951 ENSG00000143951 −554
Cerebellum rs4513466 2.39E-10 4.55E-06 −2.03E-02 4.24E-01 ENSG00000175161 ENSG00000239519 −382
Cerebellar Hemisphere rs4513466 2.39E-10 4.55E-06 −2.03E-02 5.28E-01 ENSG00000175161 ENSG00000239519 −382
Nucleus accumbens rs4513466 2.39E-10 4.55E-06 −2.03E-02 5.25E-01 ENSG00000175161 ENSG00000239519 −382
Former vs. current smoker
Whole Blood rs56113850 2.52E-26 7.40E-20 2.06E-02 9.08E-02 ENSG00000255974 ENSG00000269858 48
Brain Cerebellum rs12459249 3.89E-16 1.63E-10 1.67E-02 −4.61E-01 ENSG00000269843 ENSG00000130612 −57
Brain Cerebellum rs11697662 9.82E-15 3.60E-09 2.18E-02 5.54E-01 ENSG00000203900 ENSG00000101204 −18
Whole Blood rs7937 5.29E-11 1.55E-05 1.38E-02 −2.55E-01 ENSG00000171570 ENSG00000233622 −15
Whole Blood rs7937 5.29E-11 1.55E-05 1.38E-02 −2.16E-01 ENSG00000171570 ENSG00000188493 45
* Distance of index eQTL to transcription start site (TTS) of target gene (eGene).
Table 2
Overview of novel significant index eQTLs which were not identified by the
uninformed GWAS (FDR adj. p-value<0.05).
Trait N unique novel loci
GTEx informed
N unique novel loci DGN
informed
CPD 509 214
Alcohol consumption 949 136
Ever smoker 1335 401
Age of initiation 66 25
Former vs. current smoker 117 35
Cocaine dependence 0 0
Total 2976 811
Note: the number of unique novel loci identified by GTEx informed analyses is
based on 14 tissues, for DGN it is based on a single tissue (Whole blood).
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consumption, significant index eQTLs were observed in all brain re-
gions and in whole blood. Most of these brain regions have previously
been demonstrated to play a role in the susceptibility to alcohol use
disorders (Acheson et al., 2009; Cheetham et al., 2014; Hanson et al.,
2010; Herting et al., 2011, 2010; Sjoerds et al., 2013). Interesting
findings were index eQTLs in the putamen, caudate and cervical spine
targeting alcohol dehydrogenase 1C (ADH1C) to be significantly asso-
ciated with alcohol consumption. ADH1C was previously reported to be
associated with alcohol dependence and consumption (Clarke et al.,
2017; Frank et al., 2012; Park et al., 2013; Treutlein et al., 2009).
Moreover, we identified multiple index eQTLs targeting many different
eGenes in various tissues on chromosome 17q21.31 for alcohol con-
sumption. Chromosome 17q21.31 has been described as one of the
genome’s most structurally complex and evolutionary dynamic regions,
and genes in this region have – among other traits – been implicated in
alcohol use (Liu et al., 2019; Nelson et al., 2010; Pennisi, 2008). This
underscores the complexity of this region and of the potential im-
portance of gene regulatory mechanisms (Louro et al., 2009). Our
results, in combination with the emerging literature, suggest that this
region includes multiple functional genetic variants that contribute to
individual differences in alcohol consumption. It should be noted,
however, that previous research indicates that these regulation hotspots
should be interpreted with caution due to the complex correlation
structure of gene expression, which could lead to false positive asso-
ciations (de Koning and Haley, 2005; Peng et al., 2007).
The associations found for CPD on chromosome 15q25.1 were
magnitudes stronger than the ones found for the other substance use
traits examined in the current study (i.e., 10−40 vs 10−211). The index
eQTLs with the strongest associations, all located within the IREB2-
CHRNA3-CHRNA5-CHRNB4-HYKK-PSMA4 gene cluster, predominantly
targeted CHRNA5. This gene cluster has been associated many times in
the literature with smoking severity (Barrie et al., 2016; Furberg et al.,
2010). Our findings extend the previously observed genetic association
by showing that the CPD-associated eQTLs regulate gene expression of
CHRNA3 and CHRNA5 in striatal brain areas. A study by Barrie et al., in
which GTEx tissue-specific eQTLs from the gene cluster CHRNA5/
Table 3
Overview of the five strongest GTEx informed S-PrediXcan gene associations per substance use trait, genes printed in bold indicate significance.
Alcohol consumption
Gene Gene name Zscore Effect size Pvalue Tissue
ENSG00000035928.10 RFC1 −8.96 −3.37E-02 3.21E-19 Cerebellar Hemisphere
ENSG00000238083.3 LRRC37A2 −8.61 −2.79E-02 7.47E-18 Cerebellum
ENSG00000262539.1 RP11-259G18.3 −8.56 −1.87E-02 1.08E-17 Cerebellar Hemisphere
ENSG00000214425.2 LRRC37A4P 8.54 1.89E-02 1.36E-17 Cerebellar Hemisphere
ENSG00000263503.1 RP11-707O23.5 −8.51 −2.35E-02 1.75E-17 Cerebellar Hemisphere
CPD
ENSG00000041357.11 PSMA4 30.86 3.39E-01 4.04E-209 Whole Blood
ENSG00000041357.11 PSMA4 19.65 2.10E-01 6.10E-86 Substancia nigra
ENSG00000041357.11 PSMA4 13.88 1.09E-01 7.86E-44 Putamen
ENSG00000169684.9 CHRNA5 −13.46 −4.46E-02 2.55E-41 Substantia nigra
ENSG00000169684.9 CHRNA5 −11.22 −3.46E-02 3.31E-29 Spine
Ever smoker
ENSG00000076685.14 NT5C2 −7.99 −3.50E-02 1.35E-15 Cerebellar Hemisphere
ENSG00000166275.11 C10orf32 −7.90 −1.81E-02 2.90E-15 Cerebellum
ENSG00000166275.11 C10orf32 −7.75 −3.02E-02 9.42E-15 Whole Blood
ENSG00000235266.1 RP11-753C18.8 −7.73 −1.97E-02 1.09E-14 Cerebellar Hemisphere
ENSG00000117385.11 LEPRE1 7.68 4.13E-02 1.63E-14 Frontal Cortex
Age of initiation
ENSG00000120903.6 CHRNA2 5.71 1.61E-02 1.10E-08 Cerebellum
ENSG00000120903.6 CHRNA2 5.44 5.12E-02 5.42E-08 Caudate
ENSG00000271643.1 RP11-10C24.3 −4.89 −6.77E-02 1.01E-06 Substantia nigra
ENSG00000197386.6 HTT −4.88 −8.73E-02 1.08E-06 Whole Blood
ENSG00000120903.6 CHRNA2 4.84 1.57E-02 1.28E-06 Cerebellum
Former vs. current smoker
ENSG00000041357.11 PSMA4 6.16 5.10E-02 7.29E-10 Whole Blood
ENSG00000233622.1 CYP2T2P 5.35 3.97E-02 8.98E-08 Whole Blood
ENSG00000232630.1 PRPS1P2 −5.10 −3.44E-02 3.46E-07 Cerebellum
ENSG00000269858.1 EGLN2 −5.02 −1.51E-02 4.96E-07 Whole Blood
ENSG00000126215.9 XRCC3 5.03 2.31E-02 5.10E-07 Whole Blood
Cocaine dependence
ENSG00000257941.1 RP11-290L1.4 3.77 1.73 1.65E-04 Frontal Cortex
ENSG00000152056.12 AP1S3 3.63 2.44 2.81E-04 Whole_Blood
ENSG00000271179.1 RP11-629P16.1 −3.62 −1.29 2.95E-04 Nucleus accumbens
ENSG00000164344.11 KLKB1 −3.60 −4.0E01 3.14E-04 Cerebellum
ENSG00000169291.5 SHE −3.57 −1.46 3.62E-04 Whole Blood
The Bonferroni corrected threshold for transcriptome-wide significance (adjusted for all tissues and genes per trait) is 9.7e-7 for the GTEx analyses. Genquant gene
name (Gene); Gene name (Gene name); S-PrediXcan association result for the gene (Z-score); S-PrediXcan association effect size for the gene (Effect size); p-value for
the association statistic (P-value); number of SNPs from GWAS that were used (Number of SNPs); tissue in which the S-PrediXcan association result was found
(Tissue).
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CHRNA3/CHRNB4 were explored to investigate their role in nicotine
dependence, found significant striatal eQTLs targeting the same eGenes
(CHRNA3, CHRNA5, RP11-650L12.2) as we found here for CPD (Barrie
et al., 2016). The striatal eQTLs identified in the current study and the
findings of Barrie et al. highlight the importance of genetic regulation in
the striatum for smoking behaviors. For the other smoking related traits
no associations, comparable to the strength of those for CPD, were
found for the IREB2-CHRNA3-CHRNA5-CHRNB4-HYKK-PSMA4 gene
cluster. This suggests that vulnerability for these traits, in part, goes
through other biological pathways. This observation is in line with the
literature which shows genetic correlations between CPD and other
smoking related traits to be below 0.5 (Liu et al., 2019).
For cocaine dependence, we found no index eQTLs with significant
trait associations in the GTEx analyses. The absence of significant re-
sults is most likely due to the limited sample size of this GWAS.
However, the DGN informed analyses identified one index eQTL, which
targets the eGene C11orf9. Previously this gene has been shown to be
the target of miRNA’s which are increased in patients with alcohol use
(Miguel-Hidalgo, 2018).
We observed modest overlap between proximal genes and eGenes:
66.3 % of GTEx’s significant index eQTLs targeted eGenes other than
their proximal gene. This implies that the search for functionally re-
levant genes using GWAS results should not merely focus on physical
proximity but should instead take genetic regulation into account as an
important biological mechanism. The DGN informed single variant
analyses revealed significant eQTLs in the same traits as the GTEx
whole blood sample and also in cocaine dependence. While significant
index eQTLs were found in many of the same loci in both databases for
alcohol consumption, CPD, age of smoking initiation, ever smoker, and
former vs. current smoker, different eGenes were targeted by these
eQTLs. In fact, in 65.6 percent another eGene was targeted. This is
probably due to the fact that both GTEx and DGN are underpowered,
and thus providing incomplete, not overlapping, eQTL information.
The S-PrediXcan analyses partly confirmed the results of the single
variant eQTL analyses. For example, similar to the single variant ana-
lysis for CPD, the GTEx informed S-PrediXcan analysis identified the
genes CHRNA5, CHRNA3 and PSMA4 to be associated with CPD for
various tissues. Furthermore, for alcohol consumption, the strongest
association was found for the gene RFC1 in both the single variant and
S-PrediXcan analyses. Previous research also shown a role for RFC1 in
alcohol consumption and alcohol use disorder (Liu et al., 2019;
Sanchez-Roige et al., 2019). Noteworthy, 64.9 percent of our finding
were detected only in brain-tissues, highlighting the importance of
transcriptomic annotation, to assess the role of difficult-to-acquire tis-
sues in substance use traits. Previous research made similar observa-
tions for psychiatric disorders (Gamazon et al., 2019).
Our results suggest that whole blood may be an interesting bio-
marker for substance use traits since whole blood consistently, both in
the single variant and the S-PrediXcan analyses, showed significant
results also found other tissues. In fact, whole blood showed more
significant results than other tissues. However, this may be explained
by the larger sample size of whole blood. The significant associations in
whole blood may be due to whole blood-brain tissue eQTL overlap as a
reflection of causative brain tissue specific eQTLs, which are detectable
in whole blood, rather than pointing to a causative role for whole blood
in substance use traits (McKenzie et al., 2014; Wainberg et al., 2019).
The findings and conclusions of this study should be interpreted in
view of some key limitations. Despite the comparatively large sample
sizes of the GWAS, our study may still be underpowered to detect small
genetic effects, which is especially true for the cocaine dependence
sample. In addition, although GTEx and DGN belong to the most
comprehensive genetic expression databases, the statistical power for
eQTL discovery is still modest for some tissues (Ardlie et al., 2015). The
GTEx brain sample sizes are smaller than those for whole blood, which
is reflected in fewer identified index eQTLs in the separate brain tissues.
It is therefore likely that we tested only a subset of the total number of
true eQTLs for the various tissues. Our analyses focus on the role of
eQTLs in a wide range of tissues, however, recently it has been shown
that eQTL effects may differ between cell types within a specific tissue
(van der Wijst et al., 2018). Therefore, to better understand the role of
gene expression in substance use traits future studies should focus on
cell type specific analyses (van der Wijst et al., 2018). Furthermore, the
genes identified with the single variant and S-PrediXcan analyses
should be seen as ‘candidates’ as correlated levels of gene expression
may be observed in high LD genomic regions which makes it challen-
ging to identify the true causal genes (Wainberg et al., 2019). Moreover,
the GTEx data was composed of subjects of European ancestry, while
the GWAS results used in the current study for and cocaine dependence
are based on European and African American subjects. Since eQTLs may
not completely overlap across ethnic populations, this may have re-
duced our ability to detect novel loci. However, with sample size always
being a limiting factor in complex trait GWAS, we included the
Table 4
Number of gene discoveries from S-PrediXcan analyses and an overview of the number of significant associations in brain tissues, and whole blood.
Alcohol consumption CPD Ever vs. never smoker Age of smoking onset Former vs. current smoker Cocaine dependence
Tissue n n n n n n
Amygdala 18 4 6 0 0 0
Anterior cingulate cortex 21 6 11 0 0 0
Caudate 25 8 11 1 0 0
Cerebellar hemisphere 29 7 18 0 0 0
Cerebellum 34 8 27 1 1 0
Cortex 39 6 29 0 0 0
Frontal cortex 18 3 17 0 0 0
Hippocampus 15 7 10 0 0 0
Hypothalamus 17 4 10 0 0 0
Nucleus accumbens 21 7 4 0 0 0
Putamen 17 6 10 0 0 0
Spine 12 4 7 0 0 0
Substantia nigra 9 6 5 0 0 0
Whole blood 27 14 21 0 5 0
n unique genes ‘total’ 71 35 78 1 6 0
n unique genes brain ‘total’ 61 27 67 1 1 0
n unique genes whole blood ‘only’ 10 8 11 0 5 0
n unique genes brain ‘only’ 44 21 57 1 1 0
n unique genes ‘total’ = the number of unique genes that are significant in one or more tissues; n unique genes; n genes ‘brain’ = the number of genes that are
significant in one or more brain tissues; n genes ‘brain only’ = the number of genes that are significant in one or more brain tissues and not significant in whole blood;
n unique genes ‘whole blood’ only, the number of genes that are significant in whole blood, but not significant in any of the brain tissues.
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combined sample of European and African American subjects for co-
caine dependence to improve statistical power. By no means we claim
to present the full set of eQTLs, eGenes, and tissues involved in the
substance use traits under investigation. Therefore, the index eQTLs,
eGenes, and tissues identified by this study to be involved in substance
use traits, should be seen as ‘candidates’. Moreover, independent re-
plication of these novel candidate loci is necessary before strong con-
clusions can be drawn regarding the role of these loci in substance use
traits.
5. Conclusions
Our findings suggest that there is great value in utilizing brain and
whole blood eQTL annotations for enhancing the discovery of novel
genetic susceptibility loci for substance use traits. The tissue- focused
GTEx eQTL analyses revealed 2,976 index eQTLs which were not
identified in the discovery samples using the same threshold (FDR ad-
justed p < 0.05), implying that these candidate loci might be inter-
esting for further research. In addition, the functional annotation of
GWAS data revealed that most of the identified candidate eGenes tar-
geted by the trait-associated index eQTLs are not the nearest genes,
underscoring the importance of studying genetic regulation of gene
expression for functional annotation of genetic loci. Finally, the S-
PrediXcan results validated some of the candidate findings of the single
variant analyses. Both the single variant and gene-level analyses con-
firm the conclusions of Gamazon et al. regarding the importance of
multiple tissue eQTL investigation (Gamazon et al., 2018), as our
analyses identified many interesting (novel) candidate eGenes and tis-
sues for substance use traits. In conclusion, annotating genes based on
transcriptomic regulation in brain and non-brain tissues improves both
the identification of novel candidate genes and the functional char-
acterization of genetic risk factors for substance use traits.
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